Basic information Safety Supplier Related

Brontictuzumab

Basic information Safety Supplier Related

Brontictuzumab Basic information

Product Name:
Brontictuzumab
Synonyms:
  • Brontictuzumab
  • Research Grade Brontictuzumab(DHE48301)
  • Research Grade Brontictuzumab
  • Brontictuzumab (anti-NOTCH1)
CAS:
1447814-75-6
MW:
0
Mol File:
Mol File
More
Less

Brontictuzumab Chemical Properties

form 
Liquid
color 
Colorless to light yellow
More
Less

Brontictuzumab Usage And Synthesis

Uses

Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma[1][2][3].

in vivo

Brontictuzumab (15 mg/kg, i.p.) reduces tumor burden in T-ALL xenograft[3].
Brontictuzumab (20 mg/kg, i.p., every 4?days) inhibits DLL4 induced activation of Notch1 in MCL model[2].

Animal Model:T-ALL xenograft[3]
Dosage:15 mg/kg
Administration:Intraperitoneal injection (i.p.), twice weekly.
Result:Inhibited tumor growth and reduced the size of the spleen.
Showed massive infiltration and replacement of normal hematopoiesis by leukemia cells.
Animal Model:NSG mice injected with DLL4-stimulated NOTCH1-mutated mino cells ex vivo[2]
Dosage:20 mg/kg
Administration:Intraperitoneal injection (i.p.)
Result:Inhibited cleaved Notch1 but was not enough to cause a significant efficacy in tumor growth.

References

[1] Ferrarotto R, et al. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol. 2018 Jul 1;29(7):1561-1568. DOI:10.1093/annonc/mdy171
[2] Silkenstedt E, et al. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy. J Exp Clin Cancer Res. 2019 Nov 1;38(1):446. DOI:10.1186/s13046-019-1458-7
[3] Agnusdei V, et al. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia. 2014 Feb;28(2):278-88. DOI:10.1038/leu.2013.183

BrontictuzumabSupplier

Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Email
3008007409@qq.com
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Email
2853530910@QQ.com
Guangzhou Hongyuan Chemical Co.,Ltd
Tel
15817493340
Email
981810490@qq.com
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Email
422450190@qq.com
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com
More
Less

Brontictuzumab(1447814-75-6)Related Product Information